ArticlePloS one2017

Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733.

Emily D Crawford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.